Compare Adaptive Biotechnologies Corp (ADPT) vs Bill.com Holdings Inc (BILL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bill.com Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.06 (market cap $3.33B), while Bill.com Holdings Inc trades at $39.52 (market cap $4.05B). The key difference: Bill.com Holdings Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BILL | |
|---|---|---|
Market Cap | $3.33B | $4.05B |
Sector | Health | Technology |
52-Week High | $22.37 | $56.32 |
52-Week Low | $10.24 | $31.96 |
Enterprise Value | $3.19B | $3.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BILL Holdings trades at $40.68, up 0.49% today, with strong analyst consensus pointing to a $48 price target. The stock shows bullish technical momentum with recent earnings beats and revenue growth from $1.3B to $1.46B in 2025. Recent executive appointments and AI focus signal strategic positioning for growth.
Outlook remains positive with 56% analyst buy ratings and 36% upside potential, though high P/E of 214 and thin net margins of 0.01% pose valuation risks. Key catalysts include continued earnings outperformance and AI integration, while macroeconomic sensitivity and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →
